**Core Concept**
The question pertains to the management of co-infection, specifically the interaction between tuberculosis (TB) and human immunodeficiency virus (HIV) in an individual. The underlying principle involves the complex interplay between the host's immune system, the pathogen, and the treatment regimen.

**Why the Correct Answer is Right**
In HIV-positive patients with TB, the primary concern is the compromised immune status, which increases the risk of treatment failure and drug resistance. The use of rifampicin, an essential antitubercular drug, can induce the cytochrome P450 enzyme system, leading to decreased levels of certain antiretroviral drugs, such as protease inhibitors. This necessitates careful selection and monitoring of antiretroviral therapy (ART) and anti-TB medications to prevent treatment failures and optimize patient outcomes.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because HIV-positive patients with TB often require a combination of antiretroviral therapy (ART) and anti-TB medications, which can be challenging to manage due to drug interactions.
* **Option B:** This option is incorrect because the immune-compromised state in HIV-positive patients can lead to an increased risk of TB reactivation, not a decrease.
* **Option C:** This option is incorrect because the use of rifampicin in HIV-positive patients with TB requires close monitoring of antiretroviral drug levels to prevent treatment failures.

**Clinical Pearl / High-Yield Fact**
In HIV-positive patients with TB, it is essential to use rifampicin-sparing regimens or adjust the ART regimen to prevent drug interactions and optimize treatment outcomes. This requires close collaboration between infectious disease specialists, pulmonologists, and HIV care providers.

**Correct Answer: D.**